Suppr超能文献

一种非离子表面活性剂囊泡制剂对兔体内阿昔洛韦口服生物利用度的影响。

Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.

作者信息

Attia Ismail A, El-Gizawy Sanaa A, Fouda Medhat A, Donia Ahmed M

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, Egypt.

出版信息

AAPS PharmSciTech. 2007 Dec 14;8(4):E106. doi: 10.1208/pt0804106.

Abstract

The purpose of this research was to prepare acyclovir niosomes in a trial to improve its poor and variable oral bioavailability. The nonionic surfactant vesicles were prepared by the conventional thin film hydration method. The lipid mixture consisted of cholesterol, span 60, and dicetyl phosphate in the molar ratio of 65:60:5, respectively. The percentage entrapment was approximately 11% of acyclovir used in the hydration process. The vesicles have an average size of 0.95 microm, a most probable size of 0.8 microm, and a size range of 0.4 to 2.2 microm. Most of the niosomes have unilamellar spherical shape. In vitro drug release profile was found to follow Higuchi's equation for free and niosomal drug. The niosomal formulation exhibited significantly retarded release compared with free drug. The in vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability of acyclovir in rabbits after a single oral dose of 40 mg kg(-1). The average relative bioavailability of the drug from the niosomal dispersion in relation to the free solution was 2.55 indicating more than 2-fold increase in drug bioavailability. The niosomal dispersion showed significant increase in the mean residence time (MRT) of acyclovir reflecting sustained release characteristics. In conclusion, the niosomal formulation could be a promising delivery system for acyclovir with improved oral bioavailability and prolonged drug release profiles.

摘要

本研究的目的是制备阿昔洛韦脂质体,以改善其较差且不稳定的口服生物利用度。通过传统的薄膜水化法制备非离子表面活性剂囊泡。脂质混合物由胆固醇、司盘60和十六烷基磷酸酯组成,摩尔比分别为65:60:5。包封率约为水化过程中所用阿昔洛韦的11%。囊泡的平均大小为0.95微米,最可能大小为0.8微米,大小范围为0.4至2.2微米。大多数脂质体呈单层球形。体外药物释放曲线表明游离药物和脂质体药物均符合 Higuchi 方程。与游离药物相比,脂质体制剂的释放明显延迟。体内研究表明,单次口服剂量为40 mg kg(-1) 后,脂质体分散体显著提高了阿昔洛韦在兔体内的口服生物利用度。脂质体分散体中药物相对于游离溶液的平均相对生物利用度为2.55,表明药物生物利用度增加了两倍多。脂质体分散体显示阿昔洛韦的平均驻留时间 (MRT) 显著增加,反映了缓释特性。总之,脂质体制剂可能是一种有前景的阿昔洛韦给药系统,具有改善的口服生物利用度和延长的药物释放曲线。

相似文献

1
Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
AAPS PharmSciTech. 2007 Dec 14;8(4):E106. doi: 10.1208/pt0804106.
2
Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir.
Drug Dev Ind Pharm. 2012 Jan;38(1):84-92. doi: 10.3109/03639045.2011.592529. Epub 2011 Jul 4.
3
Preparation and characterization of niosomes containing ribavirin for liver targeting.
Drug Deliv. 2010 Jul;17(5):282-7. doi: 10.3109/10717541003706257.
4
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Int J Pharm. 2005 Dec 8;306(1-2):71-82. doi: 10.1016/j.ijpharm.2005.09.023. Epub 2005 Nov 2.
5
Enhanced oral bioavailability of griseofulvin via niosomes.
AAPS PharmSciTech. 2009;10(4):1186-92. doi: 10.1208/s12249-009-9325-z. Epub 2009 Oct 24.
6
Effect of formulation compositions on niosomal preparations.
Pharm Dev Technol. 2013 May-Jun;18(3):667-72. doi: 10.3109/10837450.2012.672988. Epub 2012 Apr 2.
7
Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
Eur J Pharm Biopharm. 2012 Jan;80(1):39-45. doi: 10.1016/j.ejpb.2011.10.001. Epub 2011 Oct 8.
9
Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir.
Drug Dev Ind Pharm. 2013 Nov;39(11):1809-17. doi: 10.3109/03639045.2012.738682. Epub 2013 Jan 2.

引用本文的文献

1
In Vitro Oral Cavity Permeability Assessment to Enable Simulation of Drug Absorption.
Pharmaceutics. 2025 Jul 17;17(7):924. doi: 10.3390/pharmaceutics17070924.
2
Nanoparticle tools for maximizing oral drug delivery.
Braz J Med Biol Res. 2025 Jun 16;58:e14459. doi: 10.1590/1414-431X2025e14459. eCollection 2025.
4
The characteristics and biological activity enhancements of melatonin encapsulations for skin care product applications.
Int J Pharm X. 2023 Oct 29;6:100217. doi: 10.1016/j.ijpx.2023.100217. eCollection 2023 Dec 15.
7
Niosomes: A Smart Drug Delivery System for Brain Targeting.
Pharm Nanotechnol. 2024;12(2):108-125. doi: 10.2174/2211738511666230524143832.
9
Strategies to improve the physicochemical properties of peptide-based drugs.
Pharm Res. 2023 Mar;40(3):617-632. doi: 10.1007/s11095-023-03486-0. Epub 2023 Mar 3.

本文引用的文献

1
Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.
Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41. doi: 10.1128/AAC.47.8.2438-2441.2003.
3
Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection.
J Chromatogr B Biomed Sci Appl. 1997 May 23;693(1):241-4. doi: 10.1016/s0378-4347(97)00041-8.
8
Species differences in the disposition of acyclovir.
Am J Med. 1982 Jul 20;73(1A):31-5. doi: 10.1016/0002-9343(82)90059-6.
9
6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.
Proc Natl Acad Sci U S A. 1984 May;81(10):3209-13. doi: 10.1073/pnas.81.10.3209.
10
Pharmacokinetics of acyclovir after intravenous and oral administration.
J Antimicrob Chemother. 1983 Sep;12 Suppl B:29-37. doi: 10.1093/jac/12.suppl_b.29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验